Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia
Schizophrenia Research · 2026-09 · 295 · 236-247
DOI: 10.1016/j.schres.2026.06.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Schizophrenia Research, 2026-09. Verfasst von Niki M Harris und 2 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Brain Institute, United States; Department of Pharmacology and Warren Center for Neuroscience Drug Discovery, United States. Electronic ad…. Hauptthemen laut MEDLINE: Schizophrenia, Receptors, Metabotropic Glutamate, Cognitive Dysfunction, Cognition Disorders. Die Arbeit nennt 226 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, NINDS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Cognitive deficits in schizophrenia are a major predictor of patient functional outcome, and current treatments have limited efficacy in targeting this symptom domain. Glutamatergic dysfunction is hypothesized to contribute to cognitive impairments, and administration of N-methyl-d-aspartate (NMDA) receptor antagonists to both healthy humans and animals causes behavioral and cognitive deficits similar to those observed in patients with schizophrenia. In particular, hypofunction of NMDA receptors on GABAergic interneurons in the medial prefrontal cortex (mPFC) leads to excessive pyramidal cell activity and is a hypothesized mechanism underlying these deficits. As such, therapeutic modulation of glutamatergic and GABAergic release in PFC-associated circuits may correct cognitive impairments in schizophrenia. Metabotropic glutamate (mGlu) receptors have emerged as a promising strategy to target this symptom domain due to their widespread expression in relevant brain regions and their implications within the glutamate system. Group III mGlu receptors (mGlu4/6/7/8) are Gi/o-coupled receptors which predominantly show presynaptic localization and are well-positioned to modulate both glutamatergic and GABAergic neurotransmission. In particular, mGlu7 is widely expressed throughout the central nervous system, including expression on neurons within relevant PFC circuits. Interestingly, schizophrenia and other neuropsychiatric disorders characterized by cognitive deficits are associated with loss-of-function variants in GRM7, the gene encoding mGlu7. Furthermore, both mGlu7 potentiation and inhibition have shown efficacy in preclinical models of neurodevelopmental and neuropsychiatric disorders characterized by cognitive impairments. Therefore, mGlu7 is proposed to be a viable therapeutic target to treat cognitive deficits driven by glutamatergic dysfunction in disorders including schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt Brain Institute, United States; Department of Pharmacology and Warren Center for Neuroscience Drug Discovery, United States. Electronic address: niki.m.harris@vanderbilt.edu.
- Department of Pharmacology and Warren Center for Neuroscience Drug Discovery, United States. Electronic address: kimberlymholter@gmail.com.
- Vanderbilt Brain Institute, United States; Department of Pharmacology and Warren Center for Neuroscience Drug Discovery, United States; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, 372…
Förderung
- NIMH NIH HHS
- NINDS NIH HHS
- National Institutes of Health
- Vanderbilt University
- National Institute of Mental Health
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Harris, N. M., Holter, K. M., & Niswender, C. M. (2026). Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia. Schizophrenia Research, 295, 236-247. https://doi.org/10.1016/j.schres.2026.06.012
Vancouver
Harris NM, Holter KM, Niswender CM. Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia. Schizophrenia Research. 2026;295:236-247. doi:10.1016/j.schres.2026.06.012
BibTeX
@article{Harris2026,
author = {Harris, Niki M and Holter, Kimberly M and Niswender, Colleen M},
title = {Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia},
journal = {Schizophrenia Research},
year = {2026},
volume = {295},
pages = {236--247},
doi = {10.1016/j.schres.2026.06.012}
}
EUVIMED